Population-Level Mortality Trends and Health Equity in Multiple Myeloma before and after CAR-T cell Approval

Key Points

• Mortality rates in multiple myeloma have shifted post CAR-T cell therapy approval, highlighting potential changes in treatment effectiveness.
• A notable increase in health equity metrics among populations with multiple myeloma suggests improved access to care over time.
• Population-level trends show a correlation between CAR-T cell therapy availability and changes in overall mortality rates.
• These findings support the need for ongoing monitoring to better understand treatment impacts on diverse groups.